Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ucan
AddedFeb 15, 2024
UpdatedJun 18, 2026
Ucan

Ucan

Series A

UCAN, a Connecticut-based pharmaceutical company, offers nutritional supplements and energy products for balanced energy and glucose control.

HQ
Woodbridge, CT, US
Founded
2010
Overview
Compare
Fundraising
Employees
Website

Founded in Woodbridge, Connecticut, UCAN is a pharmaceutical company dedicated to providing innovative nutritional supplements and energy products. The company's core mission is to help individuals achieve sustained energy, maintain balanced glucose levels, and control food cravings through scientifically-backed solutions. UCAN's product line includes sports energy drinks designed to offer long-lasting energy without the spikes and crashes associated with traditional sugary beverages. Their market focus is primarily on health-conscious consumers and athletes in the United States.

UCAN has garnered attention from notable figures in the sports and health industries, contributing to its credibility and growth. The company has achieved significant milestones, including widespread adoption among professional athletes and fitness enthusiasts. UCAN's impact is evident in its loyal customer base that values the sustained energy and health benefits its products provide. Through continuous innovation and a commitment to quality, UCAN has established itself as a trusted name in the nutritional supplement market.

Ucan - Quick Facts

When was Ucan founded?

Ucan was founded in 2010.

Where is Ucan's headquarters located?

Ucan's headquarters is located in Woodbridge, CT, US.

When was Ucan's last funding round?

Ucan's most recent funding round was for $10.7M (USD) in December 2022.

How much has Ucan raised to-date?

As of Dec 6, 2022, Ucan has raised a total of $20.8M (USD).

How many employees does Ucan have?

Ucan has 26 employees as of Feb 4, 2024.

Ucan - Classification

Ownership
  • Private
Technology
  • Data
Geographic Exposure
  • United States
Revenue
  • Transactional
Customer
  • Consumers
Main Product
  • Energy Products
  • Nutritional Supplements
Tags
  • eCommerce
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations